Meeting the Medical Needs of Patients with Ulcerative Colitis During the COVID-19 Pandemic

To participate in this activity, please start here:

The COVID-19 pandemic is an unprecedented challenge for all healthcare systems worldwide. Gastroenterologists and clinicians who actively manage patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC), need to ensure they are taking steps to minimize the risk of infection for their patients.

Russell D. Cohen, MD, shares his expert perspective as an author of the recently published AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic. Dr. Cohen highlights emerging evidence and the potential risk of IBD patients for COVID-19, as well as recommendations for the treatment and management of patients with IBD during the coronavirus pandemic. In addition, he reviews the publicly accessible SECURE-IBD international registry and its impact tracking COVID-19 in patients with IBD. Dr. Cohen further discusses how to identify, appropriately manage, and monitor patients with UC who test positive for COVID-19, through the use of an algorithm to guide complex clinical decisions for those who are symptomatic with or without suspicion of active UC inflammation.

Course Credit:

1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour

Dates:

Opens: 2020-07-17
Closes: 2021-07-16

Target Audience:

This activity was developed for gastroenterologists, physician assistants, nurse practitioners, nurses and other healthcare providers who manage patients with inflammatory bowel disease.

This activity is supported by an educational grant from Pfizer Inc.
  • Russell D. Cohen, MD

    Professor of Medicine, Pritzker School of Medicine
    Director, Inflammatory Bowel Disease Center
    Co-Director, Advanced IBD Fellowship Program
    The University of Chicago Medicine
    Chicago, Illinois

Learning Objectives

  • Summarize the relative risk and signs of SARS-CoV-2 infection among patients with ulcerative colitis (UC)
  • Modify management and education of UC patients not infected with SARS-CoV-2 in order to reduce the risk of such infection
  • Safely modify UC treatments in patients testing positive for SARS-CoV-2 but asymptomatic
  • Safely modify UC treatments in patients with symptomatic COVID-19, including those with active UC inflammation

Faculty Disclosures

Russell D. Cohen, MD

Speaker bureau

  • AbbVie – clinical area: Inflammatory Bowel Disease
  • Takeda – clinical area: Inflammatory Bowel Disease

Consultant

  •  AbbVie – clinical area: Inflammatory Bowel Disease
  • Celgene – clinical area: Inflammatory Bowel Disease
  • Entera Health – clinical area: Inflammatory Bowel Disease
  •  Hospira – clinical area: Inflammatory Bowel Disease
  • Janssen – clinical area: Inflammatory Bowel Disease
  •  Pfizer Inc. – clinical area: Inflammatory Bowel Disease
  • Sandoz – clinical area: Inflammatory Bowel Disease
  • Takeda – clinical area: Inflammatory Bowel Disease
  •  UCB – clinical area: Inflammatory Bowel Disease

Research Support 

  • AstraZeneca – clinical area: Inflammatory Bowel Disease
  • Celgene – clinical area: Inflammatory Bowel Disease
  • Gilead Sciences – clinical area: Inflammatory Bowel Disease
  • MedImmune – clinical area: Inflammatory Bowel Disease
  • Mesoblast – clinical area: Inflammatory Bowel Disease
  • Osiris Therapeutics – clinical area: Inflammatory Bowel Disease
  •  Pfizer Inc. – clinical area: Inflammatory Bowel Disease
  • Receptos – clinical area: Inflammatory Bowel Disease
  • RedHill Biopharma – clinical area: Inflammatory Bowel Disease
  • Sanofi US – clinical area: Inflammatory Bowel Disease
  • UCB – clinical area: Inflammatory Bowel Disease

Dr. Cohen’s spouse is on the board of directors for Aerpio Therapeutics, Novus Therapeutics, Vital Therapies, Inc., and NantKwest.


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 1.00 contact hour. Program ID# 5864-EM.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.00 contact hour may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Victoria Anderson (Medical Writer)
  • Individual stockholder
    • Abbott 
    • AbbVie

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Planner)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.